(Lecture) Pharmacological Targeting Cell Metabolism and Epigenetic for Triple Negative Breast Cancer Therapy
Topic: Pharmacological Targeting Cell Metabolism and Epigenetic for Triple Negative Breast Cancer Therapy
Speaker: Dr. Wu Qin (University of Toronto）
Time: Dec. 25th, 2018 (Tuesday), 10:00am
Venue: B2-101, University Town Campus
Triple negative breast cancer (TNBC) accounts for almost 20% of breast malignancies and is characterized by lack of expression of the estrogen receptor (ER) and progesterone receptor (PR) and absence of HER2 amplification. Due to the lack of targeted therapies, patients with TNBC have a poor survival rate and a larger likelihood of distant recurrence and death within five years of diagnosis. In this talk, I will show our unpublished work that GLUT1 inhibition is effective in killing a subset of TNBC cell lines and patient samples and is highly correlated with the status of the retinoblastoma gene, Rb1 (which has been previously linked to metabolism in breast cancer). I will also describe the role of the HBO1 acetylase complex in TNBC under conditions of glucose deprivation or with a selective GLUT1 inhibitor. In summary, our studies uncover novel links between epigenetics and metabolism and point to strategies for combination therapies for this deadly cancer type.
Announced by School of Biomedical Science and Engineering